Lin Zhang
Neurology · Sacramento, CANPI 1245215946
Payments from drug & device makers
Across 591 payments — averaging $1255.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$250K
- Eli Lilly$116K
- Neurocrine Biosciences, Inc.$105K
- Sage Therapeutics, LLC$100K
- Abbott$62K
- Acadia Pharmaceuticals Inc$30K
- plus $79K from 19 others
Across 1 payment — averaging $220.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$220
What the payments were for
- Consulting fees$41,03813%
- Speaking & faculty fees$223,29468%
- Travel & lodging$53,41216%
- Food & beverage$10,3943%
- Education$1080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 300 | $250,152 |
| Eli Lilly | 4 | $116,128 |
| Neurocrine Biosciences, Inc. | 45 | $104,813 |
| Sage Therapeutics, LLC | 11 | $100,172 |
| Abbott | 50 | $61,976 |
| Acadia Pharmaceuticals Inc | 45 | $29,670 |
| Adamas Pharmaceuticals, Inc. | 23 | $19,229 |
| AbbVie(2 entities) | 24 | $12,941 |
| Ipsen Biopharmaceuticals, Inc | 16 | $11,724 |
| UCB, Inc. | 13 | $9,063 |
| Kyowa Kirin, Inc. | 8 | $6,735 |
| Orphalan Inc | 6 | $5,931 |
| Lundbeck LLC | 6 | $5,558 |
| Ipsen Pharma SAS | 1 | $3,400 |
| AstraZeneca(2 entities) | 2 | $1,525 |
| Boston Scientific | 11 | $1,309 |
| Acorda Therapeutics, Inc | 7 | $815 |
| Teva Pharmaceuticals USA, Inc. | 9 | $566 |
| Beigene USA, Inc. | 1 | $150 |
| Biotronik Inc. | 4 | $106 |
| Sumitomo Pharma America, Inc. | 1 | $95 |
| Intuitive Surgical | 1 | $27 |
| Merz North America, Inc. | 1 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$742,147 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 329 | $637,565 |
| ApokynApomorphine Hcl | 34 | $574,623 |
| NourianzIstradefylline | 131 | $417,710 |
| GocovriAmantadine Hcl | 103 | $369,108 |
| Droxidopa | 108 | $291,059 |
| NuplazidPimavanserin Tartrate | 22 | $275,489 |
| IngrezzaValbenazine Tosylate | 28 | $185,217 |
| NeuproRotigotine | 122 | $161,961 |
| AustedoDeutetrabenazine | 23 | $111,655 |
| XadagoSafinamide Mesylate | 52 | $92,157 |
| InbrijaLevodopa | 18 | $62,904 |
| Tetrabenazine | 16 | $31,696 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 471 | $23,642 |
| HorizantGabapentin Enacarbil | 22 | $23,384 |
| Rasagiline Mesylate | 85 | $18,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Kyowa Kirin, Inc.Nourianz | $6,735 | $417,710131 claims |
| MDD US Operations, LLCGocovri | $250,152 | $369,108103 claims |
| Acadia Pharmaceuticals IncNuplazid | $29,670 | $275,48922 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $104,813 | $202,30640 claims |
| UCB, Inc.Neupro | $9,063 | $161,961122 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $566 | $111,65523 claims |
| Acorda Therapeutics, IncInbrija | $815 | $62,90418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.
Other neurology in Sacramento
- Michelle AppersonSacramento$2.5M
- Timothy CloughesyLos Angeles$33.1M
- Jack FlorinFullerton$13M
- David KudrowSanta Monica$12.8M
- John Ravitsla Jolla$8.4M
- Perminder BhatiaFresno$8.3M
- Perry ShiehLos Angeles$8.2M
- Benjamin FrishbergCarlsbad$8.2M
- Bruce CreeSan Francisco$8M
- Lawrence RechtPalo Alto$6.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.